Boehringer Ingelheim And Eli Lilly Diabetes Alliance To Present 33 Abstracts At The American Diabetes Association’s 77th Scientific Sessions
RIDGEFIELD, Conn., and INDIANAPOLIS, June 1, 2017 – Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY) will present 33 abstracts highlighting the companies’ wide range of diabetes treatment options at the 77th American Diabetes Association’s (ADA) Scientific Sessions® in San Diego, June 9-13.
With compounds representing several of the largest diabetes treatment classes, Boehringer Ingelheim and Lilly will feature posters, abstracts and oral presentations for their range of products, including Jardiance® (empagliflozin) tablets, Tradjenta® (linagliptin) tablets and Basaglar® (insulin glargine injection) 100 units/mL.
“Since diabetes requires a personalized treatment regimen best suited to each individual, it is important that we understand how different treatment options can help people with diabetes manage their condition,” said Thomas Seck, M.D., vice president, Clinical Development and Medical Affairs, Primary Care, Boehringer Ingelheim Pharmaceuticals, Inc. “With our broad portfolio of treatment options, we, along with Lilly, are looking forward to showcasing our research efforts and sharing new data at this year’s ADA Scientific Sessions.”
Highlighted presentations and posters include the following:
JARDIANCE Data
JARDIANCE is approved by the U.S. Food and Drug Administration to reduce the risk of cardiovascular death in adults with type 2 diabetes and established cardiovascular disease. JARDIANCE is also approved as an adjunct to diet and exercise to improve glycemic control, or blood glucose levels, in adults with type 2 diabetes.
A special session at ADA titled “What More Can We Learn from EMPA-REG?” will review new analyses from the landmark EMPA-REG OUTCOME® trial on Saturday, June 10 from 12:30-1:30 p.m. PDT/3:30-4:30 p.m. EDT. EMPA-REG OUTCOME was a long-term, multicenter, randomized, double-blind, placebo-controlled trial which investigated the effects of JARDIANCE compared with placebo when added to standard of care type 2 diabetes and cardiovascular medicines in adults with type 2 diabetes and established cardiovascular disease.
The session will include the following abstracts:
- Empagliflozin (EMPA) Reduces Heart Failure Irrespective of Control of Blood Pressure (BP), Low Density Lipoprotein Cholesterol (LDL-C), and HbA1c (Presenting author: Fitchett, D.) [1172-P]
- Empagliflozin reduces mortality in analyses adjusted for control of blood pressure (BP), low density lipoprotein cholesterol (LDL-C) and HbA1c over time (Presenting author: Zinman, B.) [1173-P]
- Reduction in cardiovascular (CV) death with empagliflozin is consistent across categories of baseline HbA1c and change in HbA1c: results from EMPA-REG OUTCOME (Presenting author: Inzucchi, S.E.) [1174-P]
- Empagliflozin and progression of kidney disease in patients at high renal risk: slope analyses from EMPA-REG OUTCOME (Presenting author: Wanner, C.) [1175-P]
- Empagliflozin and incidence of acute kidney injury: pooled safety analysis in >12,000 individuals (Presenting author: Wheeler, D.) [1176-P]
- Effect of the SGLT-2 inhibitor EMPA on vascular function and central hemodynamics in patients with type 2 diabetes (Presenting author: Schmieder, R.) [1177-P]
TRADJENTA Data
TRADJENTA is approved to lower blood sugar in adults with type 2 diabetes along with diet and exercise. A poster presentation will focus on the CARMELINA (CArdiovascular Safety & Renal Microvascular outcomE study with LINAgliptin) trial, which is investigating the impact of treatment with TRADJENTA versus placebo on top of standard of care on cardiovascular and renal outcomes.
Sunday, June 11, 12:00–1:00 p.m. PDT/3:00–4:00 p.m. EDT (general poster session)
- CARMELINA® Trial Baseline Characteristics: A Cardiovascular and Renal Microvascular Outcome Trial with Linagliptin in Patients with Type 2 Diabetes at High Vascular Risk (Presenting author: Rosenstock, J.) [1284-P]
BASAGLAR Data